Suzhou Raymon Pharmaceuticals Co. Ltd. has patented compounds reported to be useful for the treatment of ocular hypertension.

Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has identified drug-conjugates comprising a radionuclide-labeled molecular probe linked to ligand targeting fibroblast activation protein α (FAP) through a linker reported to be useful for the treatment and diagnosis of cancer.

Researchers from Huiankai (Xiamen) Pharmaceutical Technology Co. Ltd., Quanzhou Haichuang Pharmaceutical Technology Co. Ltd. and Suzhou Grandkol Pharm Technology Co. Ltd. have discovered new compounds.

Alicorn Pharmaceutical Co. Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer, genetic disorders, cardiovascular disorders, and inflammation, autoimmune, hematologic, liver and metabolic diseases, among others.

Shanghai Ruotuo Biotechnology Co. Ltd. has identified antibody-drug conjugates consisting of antibodies targeting HER2 (erbB2) covalently linked to camptothecin derivatives through a linker reported to be useful for the treatment of cancer.

Gan & Lee Pharmaceuticals Co. Ltd. has discovered proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammatory and immunological disorders.

Scientists from Shanghai Zelgen Pharmatech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd. and Zejing Pharmaceutical (Zhejiang) Co. Ltd. have presented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Scandiedge Therapeutics AB has divulged pyruvate kinase PKLR inhibitors reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.

Scientists from Luoyang Accendatech Co. Ltd. and Tianjin Accendatech Technology Co. Ltd. have disclosed fluorine-containing parthenolide derivatives and their prodrugs reported to be useful for the treatment of cancer.

Pheon Therapeutics Ltd. has identified antibody-drug conjugates comprising antibodies targeting tumor associated antigens covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.